Sanofi/ FR0000120578 /
| 2024-06-26 7:02:55 PM | Chg. -0.5000 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 95.5000USD | -0.52% | 387 Turnover: 33,266 |
-Bid Size: - | -Ask Size: - | 121.66 bill.USD | - | - |
GlobeNewswire
5:45 PM
Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Direct...
GlobeNewswire
06-21
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s ...
GlobeNewswire
06-21
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusi...
GlobeNewswire
06-20
Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
GlobeNewswire
06-18
Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Sm...
GlobeNewswire
06-11
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire
06-03
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival ...
GlobeNewswire
05-31
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire
05-31
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire
05-31
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire
05-31
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire
05-27
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire
05-21
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire
05-20
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
05-20
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire
05-20
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire
05-13
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire
05-13
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
